# Climb Bio, Inc.: overview CLYM · Nasdaq · CIK 1768446 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/clym.md) · [Financials](/companies/clym/financials.md) · [Filings](/companies/clym/filings.md) · [Insiders](/companies/clym/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.13)](/filings/0001193125-25-268086.md) | not reported | [(0.31)](/filings/0001193125-26-210357.md) | [(0.13)](/filings/0001193125-26-336774.md) | [(0.19)](/filings/0001193125-25-268086.md) | not reported | [(0.20)](/filings/0001193125-26-210357.md) | [(0.18)](/filings/0001193125-26-336774.md) | | Free cash flow | $m | [(7.6) d](/filings/0001193125-25-268086.md) | [(5.5) d](/filings/0001193125-26-092546.md) | not reported | not reported | [(12.2) d](/filings/0001193125-25-268086.md) | [(15.6) d](/filings/0001193125-26-092546.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(4.24)](/filings/0000950170-23-006279.md) | [(1.72)](/filings/0000950170-24-038023.md) | [(1.30)](/filings/0000950170-25-044350.md) | [(1.53)](/filings/0001193125-26-092546.md) | [(0.88)](/filings/0001193125-26-092546.md) | | Free cash flow | $m | not reported | not reported | [(20.6)](/filings/0000950170-25-044350.md) | [(15.6)](/filings/0001193125-26-092546.md) | [(54.5)](/filings/0001193125-26-092546.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/clym/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $147.4m | 11,300,939 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $88.5m | 6,790,364 | | Added +6,783,967 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $44.4m | 3,404,866 | | Added +3,318,921 | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $36.5m | 2,797,375 | | Added +1,267,700 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $32.7m | 2,506,000 | | New +2,506,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $30.7m | 2,354,872 | | Added +1,953,223 | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $27.5m | 2,106,000 | | New +2,106,000 | | [FRONTIER CAPITAL MANAGEMENT CO LLC](/funds/351173.md) | 2026-06-30 | $25.3m | 1,939,019 | | New +1,939,019 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.2m | 1,698,654 | | Added +519,995 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $20.6m | 1,582,291 | | New +1,582,291 | ## Recent filings [All 320 filings](/companies/clym/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 06:24 ET | [8-K](/filings/0001193125-26-430997.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-430997 | | 2026-10-23 | 17:26 ET | [8-K](/filings/0001193125-26-430681.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-430681 | | 2026-09-03 | 07:50 ET | [8-K](/filings/0001193125-26-381060.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-381060 | | 2026-08-14 | 08:30 ET | [8-K](/filings/0001193125-26-350596.md) | 8.01 Other events | 0001193125-26-350596 | | 2026-08-06 | 07:45 ET | [10-Q](/filings/0001193125-26-336774.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336774 | | 2026-08-06 | 07:35 ET | [8-K](/filings/0001193125-26-336762.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336762 | | 2026-07-07 | 16:41 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000189.md) | Ownership report, active investor, amended | 0001346824-26-000189 | | 2026-07-01 | 16:15 ET | [8-K](/filings/0001193125-26-292567.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-292567 | | 2026-06-12 | 16:36 ET | [8-K](/filings/0001193125-26-269567.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-269567 | | 2026-06-11 | 07:12 ET | [8-K](/filings/0001193125-26-266688.md) | 8.01 Other events | 0001193125-26-266688 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-092546.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1768446 - Tickers: CLYM - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 08:52 ET. No prices; not investment advice.